Neoadjuvant HER2+ | Specialty

Targeted Therapies Continue to Shape Future Breast Cancer Paradigm

March 5th 2021

With the identification of numerous molecular abnormalities that can affect treatment and the course of disease in patients with breast cancer, it’s become understood that genetic profiling can define clinical trial eligibility, the presence or absence of aberrations help to drive treatment decisions, and variants can be predictive for response or resistance.

Decision Factors for SubQ Therapy and Unmet Needs

March 5th 2021

New Indications in HER2+ Breast Cancer Spark Discussions on Selection, Safety, and Sequencing

March 4th 2021

The KATHERINE, FeDeriCa, DESTINY-Breast01, and HER2CLIMB trials have changed practice for patients with HER2-positive breast cancer for the better.

Waisman Walks Through Sequencing Strategy in Metastatic HER2-Positive Breast Cancer

March 4th 2021

James R. Waisman, MD, shares his process for matching patients with the right treatment in the metastatic setting and areas for future exploration.

Dr. Wei on Benefits of Subcutaneous Pertuzumab/Trastuzumab in HER2+ Early Breast Cancer

March 3rd 2021

Mei Wei, MD, discusses the benefits of subcutaneous administration of pertuzumab and trastuzumab in patients with HER2-positive early breast cancer.

Antibody-Drug Conjugates, TKIs Drive Improved Outcomes in HER2+ Breast Cancer

March 3rd 2021

The practice-changing treatment regimens that were evaluated in the pivotal KATHERINE, HER2CLIMB, and DESTINY-Breast01 trials in women with HER2-positive breast cancer are pushing the needle forward in making this breast cancer subtype a chronic disease.

Phase 3 FeDeriCa and PHranceSCa Trial Overviews

February 26th 2021

Novel Agents for Late-Stage HER2+ MBC

February 26th 2021

Practical Advice for Toxicity Management in HER2+ MBC

February 19th 2021

Brain Metastases Therapy in Second-Line HER2+ MBC

February 19th 2021

x